Clinical Trial Search

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants

Primary: Difference in Mucociliary Clearance (MCC) Between Visit 1A and Visit 2A — -1.50; -0.70 percentage difference of MCC

Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305

Primary: Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic — 0.019; -0.005 Litre — p=0.216

Primary: Number of Coughs Following Capsaicin Inhalation Challenge at Baseline and Following 30 Days of Treatment With Spiriva (Baseline and 30 Days) — 2.5 coughs per dose of…

Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage

Primary: Sleep Quality Using the PSQI Questionnaire — -0.5; 1 score on a scale

Primary: Number (%) of Patients With Drug-related Adverse Events (AEs) — 7; 7; 10; 14 percentage of participants

Primary: Change From Baseline in 24-hour Cough Frequency at 14 Weeks — 17.0; 17.0; 12.6; 10.6 Coughs/hour — p=0.99

Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001

Primary: 24 Hour Sputum Volume — 41.8; 23.6; 29.9; 26.2 gram — p=<0.01

Primary: Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period — -1.75; -0.73 Score…

Primary: Median Number of Exacerbations — 1; 2 exacerbations

Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations

Primary: Forced Expiratory Volume in the First Second (FEV1) — 54; 54 Percentage predicted — p=0.09

Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml

Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85

Primary: Number of Patients Who Were Cured — 91; 117 Participants — p=<0.05

Primary: Percentage of Clinical Cure (Success) at Test of Cure Visit(Clinical Per Protocol Population) — 93.0; 94.2; 7.0; 5.8 percent

Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants

Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change

Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year

Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants

Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks — -0.013; 0.116; 0.140; 0.137 Liter — p=<0.0001

Primary: Exacerbation Rate — 1.20; 1.31 exacerbation per patient year — p=0.7282

Primary: Change in Sputum Bacteria Biomass — -0.24; -0.14 log10 molecules/uL/mL

Primary: Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue. — 442.4; 427.1 CD8+ cells count

Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115

Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941